On Saturday, August 31st, SA Diabetes Advocacy and SEMDSA co-hosted an incredible full-day workshop for healthcare professionals and people living with #diabetes. 80 participants came together in Cape Town to dive deep into Continuous Glucose Monitoring (#CGM) implementation and how to improve communication between doctors and patients. Co-developed by SA Diabetes Advocacy, SEMDSA, and FIND, and with support from The Helmsley Charitable Trust, the event highlighted the importance of sharing insights, stories, and guidance to create more effective and empathetic healthcare relationships. This unique workshop was the first of its kind—opening new doors for better understanding and care!
FIND
Gemeinnützige Organisationen
Le Grand-Saconnex, Geneva 40.201 Follower:innen
Diagnosis for all
Info
FIND seeks to ensure equitable access to reliable diagnosis around the world. We connect countries and communities, funders, decision-makers, healthcare providers and developers to spur diagnostic innovation and make testing an integral part of sustainable, resilient health systems. We are co-convener of the Access to COVID-19 Tools (ACT) Accelerator diagnostics pillar, and a WHO Collaborating Centre for Laboratory Strengthening and Diagnostic Technology Evaluation. Founded in Geneva, Switzerland, in 2003, we have regional hubs in Kenya, India, South Africa and Viet Nam. With partners across the public and private sectors, we are working to make sure that everyone who needs a test can get one.
- Website
-
http://www.finddx.org
Externer Link zu FIND
- Branche
- Gemeinnützige Organisationen
- Größe
- 201–500 Beschäftigte
- Hauptsitz
- Le Grand-Saconnex, Geneva
- Art
- Nonprofit
- Gegründet
- 2003
- Spezialgebiete
- Public-private development partnership, Clinical trials, Diagnostics for diseases of poverty, Laboratory strengthening & training, Support for Success und Technology scouting
Orte
Beschäftigte von FIND
Updates
-
Excited to learn about #genomics and #sequencing? Join us for a webinar on Wednesday, September 11, where we’ll explore the power of targeted next-generation sequencing. Whether you're just starting to dip your toes into genomics or want to deepen your knowledge, this is a fantastic opportunity for communities and civil society to engage with the latest advancements in this field. Hosted by Stop TB Partnership and FIND, in partnership with USAID, Unitaid, GLI, and the New Diagnostics Working Group. Don't miss out—register now here: https://lnkd.in/e_9FEktr Get started by learning more from the video below:
Next-generation sequencing to improve diagnosis and surveillance of infectious diseases
https://www.youtube.com/
-
On Friday, 30th August, in Cape Town, we co-hosted an exciting second multi-stakeholder workshop for the ACCEDE project with SEMDSA, thanks to The Helmsley Charitable Trust ! 🎉 This workshop brought together key players from the Department of Health, academic institutions, civil society, private funders, and advocates, building on the foundation laid during last year's inaugural session. Together, we shared insights and discussed an investment case for continuous glucose monitoring (CGM) in South Africa's public health sector. One of the study’s principal investigators emphasized: “We need to find a new normal for diabetes care in South Africa that includes more than drugs. Technology and education are equally important.”💡 The energy in the room was vibrant, productive, and forward-looking, as we worked toward improving #diabetes care in!
-
🚨 The #mpox emergency is a critical reminder of the need for rapid, accurate diagnosis at the primary care level. We are working closely with partners to ensure access to testing within the first 100 days of a health emergency in line with the #100DaysMission. With mpox cases rising in the Democratic Republic of Congo and spreading to neighboring countries, the Africa CDC raised a Public Health Emergency of Continental Security on August 13, and World Health Organization declared it a Public Health Emergency of International Concern the following day. Our Mpox Taskforce activated its response plan on August 16, 2024, to fast-track diagnostic capabilities in affected countries. However, surge funding is urgently needed to expand procurement, production, and distribution of quality-assured diagnostics. Learn more about our mpox response here: https://lnkd.in/ezbwcZvG
-
Request for proposals: Shaping the future of #schistosomiasis diagnostics We are seeking a #consultant to help build a sustainable market for a new rapid diagnostic test for schistosomiasis (SCH). This vital tool will improve early detection and support #GlobalHealth initiatives, especially in low- and middle-income countries. 🔍 Scope of Work: - Supply and demand analysis for the SCH CAA RDT - Buyer landscape evaluation & country prioritization (Kenya, Nigeria, South Africa, and more) - Willingness to pay assessments - Market access strategy support 📅 Submission deadline: September 13th, 2024 📧 Send proposals to: [email protected] More details: https://lnkd.in/ePHm3gkN
-
🌍 As #ClimateChange accelerates disease spreads, especially in low- and middle-income countries, diagnostics are crucial in protecting vulnerable communities. #G20Brazil must prioritize investment in diagnostics to build resilient healthcare systems, enhance climate-adaptive surveillance, and ensure equitable access to testing. We call on the G20 to: ◼️ Assess the impact of climate change on disease prevalence. ◼️ Invest in R&D for climate-tolerant diagnostics. ◼️ Strengthen integrated surveillance using advanced diagnostic tools. ◼️ Boost regional manufacturing to secure supply chains. ◼️ Ensure equitable access to diagnostics, especially for women and girls. Read our full statement here: https://lnkd.in/e2Mfweqy Watch our video: https://lnkd.in/evBVEJ5K
Climate Change and Health at the G20
https://www.youtube.com/
-
Don't miss our upcoming webinar on 11 September, where we'll dive into the world of targeted next-generation sequencing. This is a unique chance for communities and civil society to learn about and engage with this cutting-edge technology. Brought to you by Stop TB Partnership and FIND, in collaboration with USAID, Unitaid, GLI, and the New Diagnostics Working Group. Register here: https://lnkd.in/eCsQe8nt
-
Check out this new article in The Lancet on strengthening health systems and Gavi, the Vaccine Alliance's new #pandemic fund. While the Day Zero Fund is a vital step forward, we also need to ensure health systems are strengthened in sustainable and holistic ways. Unlike #vaccines, which are a one-time event, #diagnostics require ongoing, reliable infrastructure to be effective. This underscores why health system strengthening is essential for equitable and rapid access during health crises. We look forward to working with Gavi and other #GlobalHealth partners in ensuring #HealthForAll, especially as the #mpox situation unfolds. Read the full article here: https://lnkd.in/eJtHNcMf
-
🌍See our latest intervention statement at the #G20Brazil from the side event on accelerating a #OneHealth response to antimicrobial resistance (#AMR)! Claire Wingfield, Director of Partnerships & Advocacy, emphasized the critical role of testing in combating AMR. Accurate diagnosis is key to ensuring appropriate treatment and reducing unnecessary antimicrobial use. We are calling on the G20 to: 1️⃣ Invest in equitable access to climate-tolerant, point-of-care diagnostics. 2️⃣ Strengthen laboratory capacity and build digital One Health surveillance platforms. 3️⃣ Incentivize the development of companion diagnostics and robust stewardship strategies. Here at FIND, we are dedicated to expanding access to testing at the primary care level, improving hospital diagnostics for drug-resistant infections, and advancing digital tools for AMR surveillance. As #ClimateChange fuels the spread of AMR, it's vital that we focus on vulnerable populations, including women and girls. Read the statement here: https://lnkd.in/eQFtSBYA
FIND intervention statement at the side event on accelerating a one health response to antimicrobial resistance during the 4th G20 health working group meeting - FIND
finddx.org
-
📝New paper: Expanding Xpert MTB/RIF Ultra® and LF-LAM testing for diagnosis of tuberculosis among HIV-positive adults admitted to hospitals in Tanzania and Mozambique: a randomized controlled trial (the EXULTANT trial) #Tuberculosis remains a leading cause of death among people living with #HIV, especially in hospitals where undiagnosed cases are prevalent. 🔬 What’s New? This trial tests an expanded screening strategy using three specimens—sputum, stool, and urine—with advanced molecular tests like Xpert MTB/RIF Ultra® and urine LF-LAM. The goal? To catch TB cases that current methods might miss, leading to quicker treatment and potentially saving lives. 🌍 Why It Matters: In high TB/HIV burden regions, early and accurate diagnosis is crucial. The enhanced strategy could revolutionize how TB is detected and treated among people living with HIV, reducing mortality and offering a scalable solution for other high-burden countries. Read the full paper: https://lnkd.in/edp5QKw5 Sunita S., Vinzeigh Leukes PhD, Samuel G. Schumacher, Morten Ruhwald, MD, PhD, Adam Penn-Nicholson
Expanding Xpert MTB/RIF Ultra® and LF-LAM testing for diagnosis of tuberculosis among HIV-positive adults admitted to hospitals in Tanzania and Mozambique: a randomized controlled trial (the EXULTANT trial) - BMC Infectious Diseases
bmcinfectdis.biomedcentral.com